乙型肝炎病毒与固有免疫反应的相互作用：对新治疗策略的启示。
Interplay between hepatitis B virus and the innate immune responses: implications for new therapeutic strategies.
机构信息
Key Laboratory of Medical Molecular Virology, Ministry of Education and Ministry of Health, Shanghai Medical College of Fudan University, Shanghai, 200032, China.
出版信息
Virol Sin. 2014 Feb;29(1):17-24. doi: 10.1007/s12250-014-3412-3. Epub 2014 Jan 20.
Abstract
Hepatitis B virus (HBV) infection is still a worldwide health problem; however, the current antiviral therapies for chronic hepatitis B are limited in efficacy. The outcome of HBV infection is thought to be the result of complex interactions between the HBV and the host immune system. While the role of the adaptive immune responses in the resolution of HBV infection has been well characterized, the contribution of innate immune mechanisms remains elusive until recent evidence implicates that HBV appears to activate the innate immune response and this response is important for controlling HBV infection. Here, we review our current understanding of innate immune responses to HBV infection and the multifaceted evasion by the virus and discuss the potential strategies to combat chronic HBV infection via induction and restoration of host innate antiviral responses.
摘要
乙型肝炎病毒（HBV）感染仍然是一个全球性的健康问题；然而，目前用于慢性乙型肝炎的抗病毒疗法在疗效上受到限制。HBV 感染的结果被认为是 HBV 与宿主免疫系统之间复杂相互作用的结果。虽然适应性免疫反应在 HBV 感染的清除中所起的作用已经得到很好的描述，但直到最近有证据表明 HBV 似乎激活了先天免疫反应，并且该反应对于控制 HBV 感染很重要，先天免疫机制的贡献仍然难以捉摸。在这里，我们回顾了我们目前对 HBV 感染的先天免疫反应的理解，以及病毒的多方面逃避，并讨论了通过诱导和恢复宿主先天抗病毒反应来对抗慢性 HBV 感染的潜在策略。
相似文献
1
Interplay between hepatitis B virus and the innate immune responses: implications for new therapeutic strategies.
Virol Sin. 2014 Feb;29(1):17-24. doi: 10.1007/s12250-014-3412-3. Epub 2014 Jan 20.
2
Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection.
Front Immunol. 2020 Feb 7;10:3127. doi: 10.3389/fimmu.2019.03127. eCollection 2019.
3
Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection.
Gut. 2012 Dec;61(12):1754-64. doi: 10.1136/gutjnl-2011-301073. Epub 2011 Dec 9.
4
Advances in therapeutics for chronic hepatitis B.
Hepatol Int. 2016 Mar;10(2):277-85. doi: 10.1007/s12072-015-9661-x. Epub 2015 Sep 12.
5
Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics.
Curr Opin Pharmacol. 2016 Oct;30:93-105. doi: 10.1016/j.coph.2016.07.013. Epub 2016 Sep 6.
6
Mechanisms of HBV immune evasion.
Antiviral Res. 2020 Jul;179:104816. doi: 10.1016/j.antiviral.2020.104816. Epub 2020 May 7.
7
The role of innate immunity in the immunopathology and treatment of HBV infection.
J Hepatol. 2016 Apr;64(1 Suppl):S60-S70. doi: 10.1016/j.jhep.2016.01.028.
8
Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response?
Med Microbiol Immunol. 2015 Feb;204(1):87-94. doi: 10.1007/s00430-014-0377-7. Epub 2014 Dec 16.
9
The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy.
Antiviral Res. 2012 Dec;96(3):405-13. doi: 10.1016/j.antiviral.2012.10.001. Epub 2012 Oct 13.
10
Hepatitis B virus: from immunobiology to immunotherapy.
Clin Sci (Lond). 2013 Jan;124(2):77-85. doi: 10.1042/CS20120169.
引用本文的文献
1
The Mechanism of APOBEC3B in Hepatitis B Virus Infection and HBV Related Hepatocellular Carcinoma Progression, Therapeutic and Prognostic Potential.
Infect Drug Resist. 2024 Oct 17;17:4477-4486. doi: 10.2147/IDR.S484265. eCollection 2024.
2
Innate Immunity, Inflammation, and Intervention in HBV Infection.
Viruses. 2022 Oct 17;14(10):2275. doi: 10.3390/v14102275.
3
IL-33-ST2 Axis in Liver Disease: Progression and Challenge.
Mediators Inflamm. 2017;2017:5314213. doi: 10.1155/2017/5314213. Epub 2017 Oct 18.
4
The regulatory role of protein phosphorylation in human gammaherpesvirus associated cancers.
Virol Sin. 2017 Oct;32(5):357-368. doi: 10.1007/s12250-017-4081-9. Epub 2017 Oct 30.
5
Relevance of serum interleukin-33 and ST2 levels and the natural course of chronic hepatitis B virus infection.
BMC Infect Dis. 2016 May 16;16:200. doi: 10.1186/s12879-016-1543-x.
6
Crosstalk between innate and adaptive immunity in hepatitis B virus infection.
World J Hepatol. 2015 Dec 28;7(30):2980-91. doi: 10.4254/wjh.v7.i30.2980.
7
Hepatitis B virus spliced variants are associated with an impaired response to interferon therapy.
Sci Rep. 2015 Nov 20;5:16459. doi: 10.1038/srep16459.
8
Genetic, metabolic and environmental factors involved in the development of liver cirrhosis in Mexico.
World J Gastroenterol. 2015 Nov 7;21(41):11552-66. doi: 10.3748/wjg.v21.i41.11552.
9
CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV.
Virol Sin. 2015 Oct;30(5):317-25. doi: 10.1007/s12250-015-3660-x. Epub 2015 Oct 22.
10
Hepatitis B virus polymerase disrupts K63-linked ubiquitination of STING to block innate cytosolic DNA-sensing pathways.
J Virol. 2015 Feb;89(4):2287-300. doi: 10.1128/JVI.02760-14. Epub 2014 Dec 10.
本文引用的文献
1
An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases.
Mol Ther. 2014 Feb;22(2):303-311. doi: 10.1038/mt.2013.212. Epub 2013 Sep 12.
2
Melanoma differentiation-associated gene 5 senses hepatitis B virus and activates innate immune signaling to suppress virus replication.
J Immunol. 2013 Sep 15;191(6):3264-76. doi: 10.4049/jimmunol.1300512. Epub 2013 Aug 7.
3
Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein.
PLoS Pathog. 2013;9(7):e1003494. doi: 10.1371/journal.ppat.1003494. Epub 2013 Jul 11.
4
Exosomes mediate the cell-to-cell transmission of IFN-α-induced antiviral activity.
Nat Immunol. 2013 Aug;14(8):793-803. doi: 10.1038/ni.2647. Epub 2013 Jul 7.
5
Hepatitis B virus induces IL-23 production in antigen presenting cells and causes liver damage via the IL-23/IL-17 axis.
PLoS Pathog. 2013;9(6):e1003410. doi: 10.1371/journal.ppat.1003410. Epub 2013 Jun 27.
6
Combination of DNA prime--adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model.
PLoS Pathog. 2013;9(6):e1003391. doi: 10.1371/journal.ppat.1003391. Epub 2013 Jun 13.
7
Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation.
J Immunol. 2013 May 15;190(10):5142-51. doi: 10.4049/jimmunol.1201625. Epub 2013 Apr 12.
8
Therapeutic recovery of hepatitis B virus (HBV)-induced hepatocyte-intrinsic immune defect reverses systemic adaptive immune tolerance.
Hepatology. 2013 Jul;58(1):73-85. doi: 10.1002/hep.26339. Epub 2013 May 23.
9
GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees.
Gastroenterology. 2013 Jun;144(7):1508-17, 1517.e1-10. doi: 10.1053/j.gastro.2013.02.003. Epub 2013 Feb 13.
10
New insights into how HBV manipulates the innate immune response to establish acute and persistent infection.
Antivir Ther. 2013;18(1):1-15. doi: 10.3851/IMP2542. Epub 2013 Jan 30.
Zotero 插件